ArticleApplied clinical informatics2025
Evaluating Cost Savings Associated with a Patient-Facing Asthma Mobile Health Intervention.
Article in Applied clinical informatics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The patient-facing ASTHMAXcel mobile platform has been linked to improved asthma knowledge decreased asthma-related health care utilization (emergency department [ED] visits, hospitalizations), and reduced prednisone use among adult and pediatric patient populations.Given the upfront costs associated with developing mobile health platforms, this paper seeks to estimate the savings attributable to pediatric and adult users of the ASTHMAXcel platform through decreased hospitalizations, ED visits, and prednisone use.Forty adult patients and 39 pediatric patients with asthma completed studies evaluating the effectiveness of the ASTHMAXcel mobile platform at Montefiore Medical Center. Study participants received the mobile intervention for 6 months and questionnaires were administered at baseline and follow-up visits. Using internal cost data from Montefiore and information on insurance coverage, we estimated the average costs saved by the decreases in ED visits, hospitalizations, and prednisone usage throughout the study time period.Throughout the study time period, participant exposure to ASTHMAXcel and ASTHMAXcel adventures was estimated to save a total of $367,280 with $270,732 in savings from adults' decreased asthma-related health care utilization and $96,548 from pediatric decreases in asthma-related health care utilization. The bulk of these savings estimates are driven by decreases in hospitalizations among both pediatric and adult participants during the study time frame.Given the significant economic burden of asthma treatment and management and its disproportionate impact on those who are economically disadvantaged, it is critical that asthma interventions are assessed not only for their clinical effectiveness but also for their cost-effectiveness.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.